Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2012

01-02-2012 | Review

Endothelial progenitor cells: a new player in lupus?

Authors: Sahena Haque, M Yvonne Alexander, Ian N Bruce

Published in: Arthritis Research & Therapy | Issue 1/2012

Login to get access

Abstract

Patients with systemic lupus erythematosus (SLE) have a greatly increased risk of cardiovascular disease. There is growing interest in the link between vascular damage and lupus-specific inflammatory factors. Impaired endothelial repair could account for the endothelial dysfunction in this patient group. This review describes the contribution that endothelial progenitor cells could play in the pathogenesis of premature vascular damage in this disease. The methods of isolation, detection, and characterization of endothelial progenitor cells, together with their potential role in repair of the endothelium and as a therapeutic target in SLE, are discussed.
Appendix
Available only for authorised users
Literature
1.
Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976, 60: 221-225. 10.1016/0002-9343(76)90431-9.CrossRefPubMed
2.
Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, D'Agostino RB, Kuller LH: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997, 145: 408-415.CrossRefPubMed
3.
Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999, 42: 338-346. 10.1002/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U.CrossRefPubMed
4.
Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, Senécal JL: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I.CrossRefPubMed
5.
El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, Bernstein RM, Bruce IN: Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004, 110: 399-404. 10.1161/01.CIR.0000136807.78534.50.CrossRefPubMed
6.
Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005, 352: 1685-1695. 10.1056/NEJMra043430.CrossRefPubMed
7.
Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig G: Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005, 353: 999-1007. 10.1056/NEJMoa043814.CrossRefPubMed
8.
Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC: Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood. 2005, 105: 2783-2786. 10.1182/blood-2004-08-3057.CrossRefPubMed
9.
Holmén C, Elsheikh E, Stenvinkel P, Qureshi AR, Pettersson E, Jalkanen S, Sumitran-Holgersson S: Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement. J Am Soc Nephrol. 2005, 16: 3110-3120. 10.1681/ASN.2005040347.CrossRefPubMed
10.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997, 275: 964-967. 10.1126/science.275.5302.964.CrossRefPubMed
11.
Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18: 3964-3972. 10.1093/emboj/18.14.3964.PubMedCentralCrossRefPubMed
12.
Khan SS, Solomon MA, McCoy JP: Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom. 2005, 64: 1-8.CrossRefPubMed
13.
Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, Case J: Endothelial progenitor cells: identity defined?. J Cell Mol Med. 2009, 13: 87-102.PubMedCentralCrossRefPubMed
14.
Cheng J, Baumhueter S, Cacalano G, Carver-Moore K, Thibodeaux H, Thomas R, Broxmeyer HE, Cooper S, Hague N, Moore M, Lasky LA: Hematopoietic defects in mice lacking the sialomucin CD34. Blood. 1996, 87: 479-490.PubMed
15.
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997, 90: 5002-5012.PubMed
16.
Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000, 95: 952-958.PubMed
17.
Roskoski R: VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun. 2008, 375: 287-291. 10.1016/j.bbrc.2008.07.121.CrossRefPubMed
18.
Woodfin A, Voisin MB, Nourshargh S: PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol. 2007, 27: 2514-2523. 10.1161/ATVBAHA.107.151456.CrossRefPubMed
19.
Denis CV: Molecular and cellular biology of von Willebrand factor. Int J Hematol. 2002, 75: 3-8. 10.1007/BF02981972.CrossRefPubMed
20.
Watt SM, Gschmeissner SE, Bates PA: PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. Leuk Lymphoma. 1995, 17: 229-244. 10.3109/10428199509056827.CrossRefPubMed
21.
Fernandez Pujol B, Lucibello FC, Gehling UM, Lindemann K, Weidner N, Zuzarte ML, Adamkiewicz J, Elsässer HP, Müller R, Havemann K: Endotheliallike cells derived from human CD14 positive monocytes. Diff erentiation. 2000, 65: 287-300.
22.
Romagnani P, Annunziato F, Liotta F, Lazzeri E, Mazzinghi B, Frosali F, Cosmi L, Maggi L, Lasagni L, Scheffold A, Kruger M, Dimmeler S, Marra F, Gensini G, Maggi E, Romagnani S: CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res. 2005, 97: 314-322. 10.1161/01.RES.0000177670.72216.9b.CrossRefPubMed
23.
Abu El-Asrar AM, Struyf S, Verbeke H, Van Damme J, Geboes K: Circulating bone-marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes. Acta Ophthalmol. 2011, 89: 222-228. 10.1111/j.1755-3768.2009.01700.x.CrossRefPubMed
24.
Pelliccia F, Pasceri V, Cianfrocca C, Vitale C, Pristipino C, Speciale G, Mercuro G, Rosano G: Endothelial progenitor cells in patients with coronary artery disease and left ventricular dysfunction. Coron Artery Dis. 2009, 20: 303-308. 10.1097/MCA.0b013e328325765e.CrossRefPubMed
25.
Hu T, She Q, Jiang Y, Su L, Yin Y: Level of CD14+-endothelial progenitor cells is not associated with coronary artery disease or cardiovascular risk factors. Age (Dordr). 2008, 30: 319-326. 10.1007/s11357-008-9074-z.CrossRef
26.
Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003, 348: 593-600. 10.1056/NEJMoa022287.CrossRefPubMed
27.
Lin Y, Weisdorf DJ, Solovey A, Hebbel RP: Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000, 105: 71-77. 10.1172/JCI8071.PubMedCentralCrossRefPubMed
28.
Prokopi M, Mayr M: Proteomics: a reality-check for putative stem cells. Circ Res. 2011, 108: 499-511. 10.1161/CIRCRESAHA.110.226902.CrossRefPubMed
29.
Jialal I, Fadini GP, Pollock K, Devaraj S: Circulating levels of endothelial progenitor cell mobilizing factors in the metabolic syndrome. Am J Cardiol. 2010, 106: 1606-1608. 10.1016/j.amjcard.2010.07.039.PubMedCentralCrossRefPubMed
30.
Jodon de Villeroché V, Avouac J, Ponceau A, Ruiz B, Kahan A, Boileau C, Uzan G, Allanore Y: Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity. Arthritis Res Ther. 2010, 12: R27-10.1186/ar2934.PubMedCentralCrossRefPubMed
31.
Urbich C, De Souza AI, Rossig L, Yin X, Xing Q, Prokopi M, Drozdov I, Steiner M, Breuss J, Xu Q, Dimmeler S, Mayr M: Proteomic characterization of human early pro-angiogenic cells. J Mol Cell Cardiol. 2011, 50: 333-336. 10.1016/j.yjmcc.2010.11.022.CrossRefPubMed
32.
Ingram DA, Caplice NM, Yoder MC: Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood. 2005, 106: 1525-1531. 10.1182/blood-2005-04-1509.CrossRefPubMed
33.
Rohde E, Bartmann C, Schallmoser K, Reinisch A, Lanzer G, Linkesch W, Guelly C, Strunk D: Immune cells mimic the morphology of endothelial progenitor colonies in vitro. Stem Cells. 2007, 25: 1746-1752. 10.1634/stemcells.2006-0833.CrossRefPubMed
34.
Desai A, Glaser A, Liu D, Raghavachari N, Blum A, Zalos G, Lippincott M, McCoy JP, Munson PJ, Solomon MA, Danner RL, Cannon RO 3rd: Microarraybased characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans. Arterioscler Thromb Vasc Biol. 2009, 29: 121-127. 10.1161/ATVBAHA.108.174573.PubMedCentralCrossRefPubMed
35.
Rehman J, Li J, Orschell CM, March KL: Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003, 107: 1164-1169. 10.1161/01.CIR.0000058702.69484.A0.CrossRefPubMed
36.
Burt RK, Testori A, Oyama Y, Rodriguez HE, Yaung K, Villa M, Bucha JM, Milanetti F, Sheehan J, Rajamannan N, Pearce WH: Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant. 2010, 45: 111-116. 10.1038/bmt.2009.102.PubMedCentralCrossRefPubMed
37.
Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, Iida J, Sakata H, Onodera K, Tamaki T, Furui H, Kukita K, Meguro J, Yonekawa M, Tanaka S: Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs. 2006, 9: 226-233. 10.1007/s10047-006-0351-2.CrossRefPubMed
38.
Hernández P, Cortina L, Artaza H, Pol N, Lam RM, Dorticós E, Macias C, Hernández C, del Valle L, Blanco A, Martinez A, Diáz F: Autologous bonemarrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis. 2007, 194: e52-e56. 10.1016/j.atherosclerosis.2006.08.025.CrossRefPubMed
39.
Assmus B, Rolf A, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Tillmanns H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Tonn T, Dimmeler S, Dill T, Zeiher AM, Schächinger V, REPAIR-AMI Investigators: Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 2010, 3: 89-96. 10.1161/CIRCHEARTFAILURE.108.843243.CrossRefPubMed
40.
Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, De Bondt P, Van Haute I, Lootens N, Heyndrickx G, Wijns W: Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation. 2005, 112 (9 Suppl): I178-I183.PubMed
41.
Kirton JP, Xu Q: Endothelial precursors in vascular repair. Microvasc Res. 2010, 79: 193-199. 10.1016/j.mvr.2010.02.009.CrossRefPubMed
42.
Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, Inden Y, Murohara T: Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol. 2004, 24: 1442-1447. 10.1161/01.ATV.0000135655.52088.c5.CrossRefPubMed
43.
Lenk K, Uhlemann M, Schuler G, Adams V: Role of endothelial progenitor cells in the beneficial effects of physical activity on atherosclerosis and coronary artery disease. J Appl Physiol. 2011, 111: 321-328.CrossRefPubMed
44.
Reinhard H, Jacobsen PK, Lajer M, Pedersen N, Billestrup N, Mandrup-Poulsen T, Parving HH, Rossing P: Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. Diabetologia. 2010, 53: 2129-2133. 10.1007/s00125-010-1843-4.CrossRefPubMed
45.
Muller P, Kazakov A, Jagoda P, Semenov A, Bohm M, Laufs U: ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. Cardiovasc Res. 2009, 83: 106-114. 10.1093/cvr/cvp123.CrossRefPubMed
46.
Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S: Vascular trauma induces rapid but transient mobilization of VEGFR2+AC133+ endothelial precursor cells. Circ Res. 2001, 88: 167-174.CrossRefPubMed
47.
Yip HK, Tsai TH, Lin HS, Chen SF, Sun CK, Leu S, Yuen CM, Tan TY, Lan MY, Liou CW, Lu CH, Chang WN: Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. Crit Care. 2011, 15: R40-10.1186/cc10002.PubMedCentralCrossRefPubMed
48.
Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001, 89: E1-E7. 10.1161/hh1301.093953.CrossRefPubMed
49.
Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC: Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis. 2007, 66: 865-870. 10.1136/ard.2006.065631.PubMedCentralCrossRefPubMed
50.
Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ: Interferon-{alpha} promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007, 110: 2907-2915. 10.1182/blood-2007-05-089086.PubMedCentralCrossRefPubMed
51.
Moonen JR, de Leeuw K, van Seijen XJ, Kallenberg CG, van Luyn MJ, Bijl M, Harmsen MC: Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther. 2007, 9: R84-10.1186/ar2283.PubMedCentralCrossRefPubMed
52.
Baker JF, Zhang L, Imadojemu S, Sharpe A, Patil S, Moore JS, Mohler ER 3rd, Von Feldt J: Circulating endothelial progenitor cells are reduced in SLE in the absence of coronary artery calcification. Rheumatol Int. 2011,
53.
Deng XL, Li XX, Liu XY, Sun L, Liu R: Comparative study on circulating endothelial progenitor cells in systemic lupus erythematosus patients at active stage. Rheumatol Int. 2010, 30: 1429-1436. 10.1007/s00296-009-1156-4.CrossRefPubMed
54.
Grisar J, Steiner CW, Bonelli M, Karonitsch T, Schwarzinger I, Weigel G, Steiner G, Smolen JS: Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology. 2008, 47: 1476-1483. 10.1093/rheumatology/ken286.CrossRefPubMed
55.
Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Levartovski D, Caspi D, George J: Enhanced adhesive properties of endothelial progenitor cells (EPCs) in patients with SLE. Rheumatol Int. 2011, 31: 773-778. 10.1007/s00296-010-1377-6.CrossRefPubMed
56.
Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, Segal MS: Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007, 56: 3759-3769. 10.1002/art.23035.CrossRefPubMed
57.
Ebner P, Picard F, Richter J, Darrelmann E, Schneider M, Strauer BE, Brehm M: Accumulation of VEGFR-2+/CD133+ cells and decreased number and impaired functionality of CD34+/VEGFR-2+ cells in patients with SLE. Rheumatology (Oxford). 2010, 49: 63-72. 10.1093/rheumatology/kep335.CrossRef
58.
Haque S, Rakieh C, Parker B, Jackson M, Day P, Alexander YM, Bruce IN: Endothelial cell abnormalities in SLE. Lupus. 2010, 19 (1 suppl): 1-185.CrossRef
59.
Hall JC, Rosen A: Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol. 2010, 6: 40-49. 10.1038/nrrheum.2009.237.PubMedCentralCrossRefPubMed
60.
Lindner DJ: Interferons as antiangiogenic agents. Curr Oncol Rep. 2002, 4: 510-514. 10.1007/s11912-002-0065-4.CrossRefPubMed
61.
Banchereau J, Pascual V: Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006, 25: 383-392. 10.1016/j.immuni.2006.08.010.CrossRefPubMed
62.
Thacker SG, Duquaine D, Park J, Kaplan MJ: Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus. 2010, 19: 288-299. 10.1177/0961203309353773.PubMedCentralCrossRefPubMed
63.
Lian ZX, Kikuchi K, Yang GX, Ansari AA, Ikehara S, Gershwin ME: Expansion of bone marrow IFN-alpha-producing dendritic cells in New Zealand Black (NZB) mice: high level expression of TLR9 and secretion of IFN-alpha in NZB bone marrow. J Immunol. 2004, 173: 5283-5289.CrossRefPubMed
Metadata
Title
Endothelial progenitor cells: a new player in lupus?
Authors
Sahena Haque
M Yvonne Alexander
Ian N Bruce
Publication date
01-02-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3700

Other articles of this Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue

Research article

Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs

Research article

International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis

Editorial

The BRIC-GARN Meeting 2011: of mice and men

Research article

Tight regulation of wingless-type signaling in the articular cartilage - subchondral bone biomechanical unit: transcriptomics in Frzb-knockout mice

Research article

Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis

Research article

The distribution pattern of critically short telomeres in human osteoarthritic knees
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits